AdAlta Ltd. ( (AU:1AD) ) just unveiled an announcement.
AdAlta Limited has received a $424,600 advance on its FY25 R&D Tax Incentive rebate through a loan facility with Radium Capital. This funding will support the company’s due diligence and negotiation efforts for three cellular immunotherapy products under its ‘East to West’ strategy, aimed at addressing the underserved market of solid cancer treatments. The advance will facilitate the progression of these products, which are the first to emerge from this strategy, potentially strengthening AdAlta’s position in the rapidly growing cellular immunotherapy sector.
More about AdAlta Ltd.
AdAlta Limited is a clinical stage biotechnology company focused on developing effective cellular immunotherapies for solid cancers. The company employs an ‘East to West’ strategy, integrating Asian T cell therapy innovations with Australia’s clinical and manufacturing strengths to connect Eastern innovations with Western markets. AdAlta aims to dominate the high-growth cellular immunotherapy market, which is projected to reach US$20.3 billion by 2028, by focusing on differentiated T cell therapies and a capital-efficient business model.
YTD Price Performance: -30.0%
Average Trading Volume: 376,364
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$8.85M
Find detailed analytics on 1AD stock on TipRanks’ Stock Analysis page.